Darolutamide Plus ADT/Docetaxel Produces Durable PSA Responses in mHSPC
April 29th 2023A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.
Read More
Long-Term JAVELIN Bladder 100 Data Support Avelumab Maintenance in Advanced Urothelial Carcinoma
April 28th 2023First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.
Read More
Predictive, Prognostic Models May Tailor Neoadjuvant Approach in HER2+ Breast Cancer
March 3rd 2023With the advent of effective drug regimens to treat HER2-positive breast cancer, the use of tailored efforts with neoadjuvant therapy in this space may continue to improve efficacy moving forward.
Read More
Ide-Cel Improves PFS and ORR in Triple-Class Exposed, Early R/R Multiple Myeloma
February 19th 2023Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Read More
Chronic Opioid Use Following ASCT Linked With Poor Survival Outcomes in Multiple Myeloma
February 18th 2023Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.
Read More
Tucatinib Plus Trastuzumab Elicits Responses in Crossover Cohort in HER2+ mCRC
September 12th 2022Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.
Read More
Cabozantinib Improves PFS Outcomes With Nivolumab, Ipilimumab in Advanced RCC
September 12th 2022The triplet regimen of cabozantinib plus standard-of-care nivolumab and ipilimumab reduced the risk of disease progression or death by 27% vs placebo in patients with advanced renal cell carcinoma.
Read More
Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC
September 11th 2022The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.
Read More
The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.
Read More
Exposure to Environmental Carcinogens May Increase Risk for EGFR+ NSCLC
September 10th 2022Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.
Read More
Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.
Read More
Dostarlimab Demonstrates Promising Response Rates in Advanced, Recurrent Endometrial Cancer
June 8th 2022Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease.
Read More
Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid Tumors
June 7th 2022A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.
Read More
Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC
June 3rd 2022Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.
Read More
Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC
April 13th 2022The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.
Read More
NCCN Guidelines: How to Shared Decisions in Metastatic TNBC Treatment
December 17th 2021As part of its CURE Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about shared-decision making with the NCCN guidelines on metastatic triple-negative breast cancer.
Read More
Ibrutinib Plus FCR Shows Encouraging Activity as Time-Limited Option for Younger Patients With CLL
December 13th 2021The addition of ibrutinib to fludarabine, cyclophosphamide, and rituximab resulted in a higher rate of complete responses with bone marrow undetectable minimal residual disease in younger, fit patients with chronic lymphocytic leukemia.
Read More